Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
39.44
+0.87 (2.26%)
Mar 6, 2026, 2:57 PM EST - Market open
Soleno Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 190.41 | - | - | - | - | Upgrade
|
| Cost of Revenue | 2.7 | - | - | - | - | Upgrade
|
| Gross Profit | 187.71 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 132.13 | 105.86 | 13.48 | 9.84 | 10.81 | Upgrade
|
| Research & Development | 40.63 | 78.57 | 25.19 | 15.27 | 21.45 | Upgrade
|
| Operating Expenses | 172.76 | 184.43 | 38.67 | 25.11 | 32.26 | Upgrade
|
| Operating Income | 14.95 | -184.43 | -38.67 | -25.11 | -32.26 | Upgrade
|
| Interest Expense | -5.48 | -0.23 | - | - | - | Upgrade
|
| Interest & Investment Income | 16.95 | 12.05 | 2.58 | 0.3 | 0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0.18 | 0.03 | 0.51 | Upgrade
|
| EBT Excluding Unusual Items | 26.43 | -172.61 | -36.27 | -24.78 | -31.64 | Upgrade
|
| Other Unusual Items | -5.54 | -3.24 | -2.71 | 0.71 | 0.73 | Upgrade
|
| Pretax Income | 20.89 | -175.85 | -38.99 | -24.07 | -30.91 | Upgrade
|
| Earnings From Continuing Operations | 20.89 | -175.85 | -38.99 | -24.07 | -30.91 | Upgrade
|
| Net Income | 20.89 | -175.85 | -38.99 | -24.07 | -30.91 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.42 | - | - | - | - | Upgrade
|
| Net Income to Common | 20.48 | -175.85 | -38.99 | -24.07 | -30.91 | Upgrade
|
| Shares Outstanding (Basic) | 51 | 40 | 16 | 8 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 52 | 40 | 16 | 8 | 5 | Upgrade
|
| Shares Change (YoY) | 30.39% | 143.61% | 96.40% | 57.90% | 27.39% | Upgrade
|
| EPS (Basic) | 0.40 | -4.38 | -2.36 | -2.87 | -5.81 | Upgrade
|
| EPS (Diluted) | 0.39 | -4.38 | -2.36 | -2.87 | -5.81 | Upgrade
|
| Free Cash Flow | 46.73 | -69.31 | -24.94 | -20.79 | -27.79 | Upgrade
|
| Free Cash Flow Per Share | 0.89 | -1.73 | -1.51 | -2.48 | -5.23 | Upgrade
|
| Gross Margin | 98.58% | - | - | - | - | Upgrade
|
| Operating Margin | 7.85% | - | - | - | - | Upgrade
|
| Profit Margin | 10.75% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 24.54% | - | - | - | - | Upgrade
|
| EBITDA | 16.97 | -182.44 | -36.71 | -23.15 | -30.3 | Upgrade
|
| EBITDA Margin | 8.91% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 2.02 | 1.99 | 1.96 | 1.96 | 1.96 | Upgrade
|
| EBIT | 14.95 | -184.43 | -38.67 | -25.11 | -32.26 | Upgrade
|
| EBIT Margin | 7.85% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.